157 related articles for article (PubMed ID: 36800111)
1. Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials.
Ji Y; Yartsev V; Quinlan M; Serra P; Wang Y; Chakraborty A; Miller M
Clin Pharmacokinet; 2023 Mar; 62(3):493-504. PubMed ID: 36800111
[TBL] [Abstract][Full Text] [Related]
2. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.
Ji Y; Darstein C; Yang S; Quinlan M; Chakravartty A; Zarate JP; Chakraborty A; Ho YY
J Clin Pharmacol; 2023 Dec; 63(12):1359-1370. PubMed ID: 37464901
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
5. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Yap YS; Chiu J; Ito Y; Ishikawa T; Aruga T; Kim SJ; Toyama T; Saeki T; Saito M; Gounaris I; Su F; Ji Y; Han Y; Gazdoiu M; Masuda N
Cancer Sci; 2020 Sep; 111(9):3313-3326. PubMed ID: 32619077
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Samant TS; Yang S; Miller M; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1001-1009. PubMed ID: 33555033
[TBL] [Abstract][Full Text] [Related]
8. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
André F; Su F; Solovieff N; Hortobagyi G; Chia S; Neven P; Bardia A; Tripathy D; Lu YS; Lteif A; Taran T; Babbar N; Slamon D; Arteaga CL
Ann Oncol; 2023 Nov; 34(11):1003-1014. PubMed ID: 37673211
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S; Palacova M; Łacko A; Timcheva C; Gal-Yam EN; Papazisis K; Beniak J; Kudela P; Rubovszky G
Radiol Oncol; 2022 May; 56(2):238-247. PubMed ID: 35575587
[TBL] [Abstract][Full Text] [Related]
11. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
[TBL] [Abstract][Full Text] [Related]
12. MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Yardley DA
Future Oncol; 2019 Aug; 15(23):2673-2686. PubMed ID: 31305131
[TBL] [Abstract][Full Text] [Related]
13. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Sondhi M; Wang Y; Chakravartty A; Rodriguez-Lorenc K; Taran T; Jerusalem G
N Engl J Med; 2020 Feb; 382(6):514-524. PubMed ID: 31826360
[TBL] [Abstract][Full Text] [Related]
14. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Burris HA; Chan A; Bardia A; Thaddeus Beck J; Sohn J; Neven P; Tripathy D; Im SA; Chia S; Esteva FJ; Hart L; Zarate JP; Ridolfi A; Lorenc KR; Yardley DA
Br J Cancer; 2021 Aug; 125(5):679-686. PubMed ID: 34158598
[TBL] [Abstract][Full Text] [Related]
15. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Im SA; Lu YS; Bardia A; Harbeck N; Colleoni M; Franke F; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva-Vazquez R; Jung KH; Chakravartty A; Hughes G; Gounaris I; Rodriguez-Lorenc K; Taran T; Hurvitz S; Tripathy D
N Engl J Med; 2019 Jul; 381(4):307-316. PubMed ID: 31166679
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
19. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
[TBL] [Abstract][Full Text] [Related]
20. Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Lu Y; Yang S; Ho YY; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1054-1068. PubMed ID: 33713359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
